
|Videos|February 9, 2016
Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in Glioblastoma
Author(s)Michael Lim, MD
Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma.
Advertisement
Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma. Lim says medical professionals should be aware of the toxicities that come along with these checkpoint inhibitors, as well as be able to recognize the first signs of toxicities.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
Linvoseltamab Monotherapy Effective in Newly Diagnosed Multiple Myeloma
3
NCCN Guidelines in nccRCC Weigh New Data for Combinations
4
Subcutaneous Cevostamab Shows Early Promise in R/R Myeloma
5









































